Document Archive

Clinical breakpoints (v 14.0) - file for printing (1 Jan, 2024 - 31 Dec 2024)
Clinical breakpoints (v 14.0) - file for screen (1 Jan, 2024 - 31 Dec 2024)
Aztreonam-avibactam - Addendum (22 May, 2024).
Cefepime-enmetazobactam - Addendum (22 May, 2024).
Dosages (v 14.0) - file for printing and screen (1 Jan, 2024).
Clinical breakpoints - bacteria (v 13.1) - file for printing (1 Jan - 31 Dec, 2023). Breakpoints for anaerobic bacteria added in June, 2023.
Clinical breakpoints - bacteria (v 13.1) - file for screen (1 Jan - 31 Dec, 2023). Breakpoints for anaerobic bacteria added in June, 2023.
Clinical breakpoints - bacteria (v 12.0) - file for printing (1 Jan - 31 Dec, 2022)
Clinical breakpoints - bacteria (v 12.0) - file for screen (1 Jan - 31 Dec, 2022)
Clinical breakpoints - bacteria (v 11.0) - file for printing (1 Jan - 31 Dec, 2021)
Clinical breakpoints - bacteria (v 11.0) - file for screen (1 Jan - 31 Dec, 2021)
Clinical breakpoints - bacteria (v 10.0) - pdf for printing (1 Jan - 31 Dec, 2020)
Erratum: In the 2020 breakpoint table, imipenem-relebactam breakpoints under Enterobacterales, should read "valid except for Morganellaceae".
Addendum: Temocillin breakpoints and AST methods (21 April, 2020)
Addendum: Cefiderocol breakpoints and AST methods (30 April, 2020)
Addendum: Ceftolozane-tazobactam zone diameter breakpoints for H. influenzae (16 June, 2020)
Clinical breakpoints - bacteria (v 10.0) - excel file for screen (1 Jan - 31 Dec, 2020). For opening the Excel file, use only the original Microsoft^TMExcel® programme - otherwise some functions may be lost.
Erratum: In the 2020 breakpoint table, imipenem-relebactam breakpoints under Enterobacterales, should read "valid except for Morganellaceae".
Addendum: Temocillin breakpoints and AST methods (21 April, 2020)
Addendum: Cefiderocol breakpoints and AST methods (30 April, 2020)
Addendum: Ceftolozane-tazobactam zone diameter breakpoints for H. influenzae (16 June, 2020)
Clinical breakpoints - bacteria (v 9.0) (until 31 Dec, 2019) - for Printing.
Clinical breakpoints - bacteria (v 9.0) (until 31 Dec, 2019) - for screen.
Clinical breakpoints - bacteria (v 8.1) (until 31 Dec, 2018) - for printing
Clinical breakpoints - bacteria (v 8.1) (until 31 Dec, 2018) - for screen
Clinical breakpoints - bacteria (v 8.0) (until 16 May, 2018) - for printing
Clinical breakpoints - bacteria (v 8.0) (until 16 May, 2018) . for screen
Clinical breakpoints - bacteria (v 7.1) (until 31 Dec, 2017) - for printing
Clinical breakpoints - bacteria (v 7.1) (until 31 Dec, 2017) - for screen
Clinical breakpoints - bacteria v 6.0 (until Dec 31, 2016) - for printing
Clinical breakpoints - bacteria v 6.0 (until Dec 31, 2016) - for screen
Clinical breakpoints - bacteria v 5.0 (until Dec 31, 2015) - for printing
Clinical breakpoints - bacteria v 5.0 (until Dec 31, 2015) - for screen
Clinical breakpoints - bacteria v 4.0 (until Dec 31, 2014) - for printing
Clinical breakpoints - bacteria v 4.0) (until Dec 31, 2014) - for screen
Clinical breakpoints - bacteria v 3.1 (until Dec 31, 2013) - for printing
Clinical breakpoints - bacteria v 3.1 (until Dec 31, 2013) - for screen
Clinical breakpoints - bacteria v 2.0 (until Dec 31, 2012) - for printing
Clinical breakpoints - bacteria v 2.0 (until Dec 31, 2012) - for screen
Clinical breakpoint tables v 1.3 (until Dec 31, 2011) - for printing
Clinical breakpoint tables v 1.3 (until Dec 31, 2011) - for screen
EUCAST breakpoint tables v 1.2 (until Jan 5, 2011)
EUCAST breakpoint tables v 1.1 (until Dec 21, 2010)
EUCAST breakpoint tables v 1.0 (until Apr 27, 2010)

QC tables 14.0 (2024-01-01 - 2024-12-31)
QC tables 13.2 (2023-06-29 - 2023-12-31) added recommendations for anaerobic QC strains.
QC tables 13.1 (2023-03-13 - 2023-06-29)
QC tables v 13.0 (2023-01-02 - 2023-03-13)
QC tables v 12.0 (2022-01-01 - 2022-12-31)
QC tables v 11.0 (2021-01-01 - 2021-12-31)
QC tables v 10.0 (2020-01-01 - 2020-12-31)
QC tables v 9.1 (2019-01-01 - 2019-12-31)
QC Tables v 9.0 (until 2019-12-31
QC Tables v 8.0 (until 2018-12-31)
QC Tables v 7.0 (until 2018-01-03)
QC Tables v 6.1 (until 2016-12-31)
QC Tables v 5.0 (until 2016-01-10)
QC Tables v 4.0 (until 2015-01-11)
Extended QC Tables v 1.0 (until 2015-01-11)
QC Tables v 3.1 (until 5 September, 2014)
QC Tables v 2.1 (until 21 December, 2012)
QC Tables v 2.0 (until 29 June, 2012)
QC Tables v 1.3 (until 1 January, 2012)
QC Tables v 1.2 (until 21 December, 2010)
QC Tables v 1.1 (until 27 April, 2010)
QC Tables v 1.0

Stenotrophomonas maltophilia (1 February 2012)
Guidance on the use of fosfomycin intravenously (5 December 2023)
Setting breakpoints for agent-inhibitor combinations (2 October 2017)
Implementation and use of the colistin breakpoints (November 2021)
Legionella pneumophila susceptibility testing (11 December 2017)
Guidance on tigecycline dosing (23 December 2018)
EUCAST system for antimicrobial name abbreviations (13 July 2018)
Oral cephalosporins and Enterobacterales breakpoints (16 February 2012)
Phenotypic screening tests to detect and exclude resistance of clinical relevance:
When there are no breakpoints:

Enterobacterales (January, 2023); Enterobacterales (June, 2019)
Enterococcus spp. (January, 2023); Enterococcus spp. (June, 2019)
EUCAST Expert rules v 3.2 (February, 2020)
EUCAST Expert rules v 3.1 (September, 2016)
EUCAST Expert rules (version 2.0 October, 2011)
EUCAST Expert rules (version 1.0 )

Amikacin 3.0 (2024-01-04), v 2.0 (2020-04-30)
Cefiderocol v 1.1 (2022-03-11)
Daptomycin v 1.0
Delafloxacin v 1.1 (2021-04-17); v 1.0 (2021-02-08)
Doripenem v 1.0 (2009-06-01)
Ertapenem v 2.0 (2021-02-08)
Gentamicin v 3.0 (2024-01-04), v 2.0 (2020-04-30)
Imipenem v 2.0 (2021-02-08)
Imipenem-relebactam v 2.0 (2024-01-04); v. 1.0 (2021-02-08)
Meropenem v 2.0 (2021-02-08)
Meropenem-vaborbactam v 1.0 (2021-02-08)
Netilmicin v 1.1 (2020-01-21)
Tigecycline v 2.0 (2022-07-21)
Tobramycin v 3.0 (2024-01-04), v 2.0 (2020-04-30)

Disk diffusion manual v 12.0 (1 January, 2024)
Disk diffusion - Slide show v 12.0 (1 January, 2024)
Disk diffusion - Reading guide v 10.0 (2 January, 2023)
Disk diffusion manual v 11.0 (2 January, 2023)
Disk diffusion - Slide show v 11.0 (2 January, 2023)
Disk diffusion - Manual v 10.0 (1 January, 2022)
Disk diffusion - Slide show v 10.0 (1 January, 2022)
Disk diffusion - Reading guide v 9.0 (1 January 2022)
Anaerobic bacteria - disk diffusion methodology v 1.0 (1 January 2022)
Anaerobic bacteria - disk diffusion reading guide v 1.0 (1 January 2022)
Disk diffusion breakpoints for anaerobic bacteria are only valid for FAA with 5% mechanically defibrinated horse blood as the only additive.
Disk diffusion - Manual v 9.0 (1 January, 2021)
Disk diffusion - Slide show v 9.0 (1 January, 2021)
Disk diffusion - Reading guide v 8.0 (1 January, 2021)
Disk Diffusion - Manual v 8.0 (1 January, 2020)
Disk Diffusion - Slide Show v 8.0 (1 January, 2020)
Disk Diffusion - Reading Guide v 7.0 (1 January, 2020)
Disk Diffusion - Manual v 7.0 (3 January - 31 December, 2019)
Disk Diffusion - Slide Show (3 January - 31 December, 2019)
Disk Diffusion - Reading Guide (3 January - 31 December, 2019)
Disk Diffusion - Manual v 6.0 (9 January, 2017 - 3 January, 2019)
Disk Diffusion - Slide Show (9 January, 2017 - 3 January, 2019)
Disk Diffusion - Reading Guide v 6.0 (9 January, 2017 - 3 January, 2019)
Disk Diffusion - Manual v 5.0 (26 January, 2015 - 9 January, 2017)
Disk Diffusion Manual v 4.0 (June 2014 - December 2014)
Disk Diffusion Manual v 3.0 (April 2013 - May 2014)
Disk Diffusion Manual v 2.0 (January 2012 - March 2013)
Disk Diffusion Manual v 1.0 (December 2009 - December 2011)
Preparation of agar plates and broth for EUCAST AST v 6.0 (1 January, 2020 - 31 December 2021)
Preparation of agar plates and broth for EUCAST AST v 5.0 (9 January, 2017 - 31 January, 2019)

Enterobacterales
Salmonella spp
Yersinia enterocolitica
Plesiomonas shigelloides
Pseudomonas aeruginosa
Pseudomonas non-aeruginosa
Stenotrophomonas maltophilia (see separate presentation of cefiderocol)
Acinetobacter spp. (see separate presentation of cefiderocol)
Staphylococcus aureus
Staphylococcus, coagulase-negative
Staphylococcus saprophyticus
Staphylococcus pseudintermedius
Enterococcus spp.
Streptococcus pyogenes (group A)
Streptococcus agalactiae
Streptococcus pneumoniae
Streptococcus pneumoniae - screen for beta-lactam resistance
Viridans Group Streptococci
Haemophilus influenzae
Haemophilus influenzae - screen for betalactam resistance
Moraxella catarrhalis
Anaerobic bacteria (Bacteroides spp, Prevotella spp, Fusobacterium necrophorum, Clostridium perfringens, Cutibacterium acnes).
Listeria monocytogenes
Pasteurella spp.
Campylobacter jejuni and C. coli
Corynebacterium spp. (other than C.diphtheriae and C.ulcerans)
Corynebacterium diphtheriae and C. ulcerans
Aerococcus sanguinicola and A. urinae
Kingella kingae
Aeromonas spp.
Achromobacter xylosoxidans
Vibrio spp.
Bacillus spp.
Burkholderia pseudomallei
Brucella melitensis - to be published during 2024
Bacillus anthracis - to be published during 2024

Enterobacterales
Salmonella spp
Yersinia enterocolitica
Plesiomonas shigelloides
Pseudomonas aeruginosa
Pseudomonas non-aeruginosa
Stenotrophomonas maltophilia (see separate presentation of cefiderocol)
Acinetobacter spp. (see separate presentation of cefiderocol)
Staphylococcus aureus
Staphylococcus, coagulase-negative
Staphylococcus saprophyticus
Staphylococcus pseudintermedius
Enterococcus spp.
Streptococcus pyogenes (group A)
Streptococcus agalactiae
Streptococcus pneumoniae
Streptococcus pneumoniae - screen for beta-lactam resistance
Viridans Group Streptococci
Haemophilus influenzae
Haemophilus influenzae - screen for betalactam resistance
Moraxella catarrhalis
Anaerobic bacteria (Bacteroides spp, Prevotella spp, Fusobacterium necrophorum, Clostridium perfringens, Cutibacterium acnes).
Listeria monocytogenes
Pasteurella spp.
Campylobacter jejuni and C. coli
Corynebacterium spp. (other than C.diphtheriae and C.ulcerans)
Corynebacterium diphtheriae and C. ulcerans
Aerococcus sanguinicola and urinae
Kingella kingae
Aeromonas spp.
Achromobacter xylosoxidans
Vibrio spp.
Bacillus spp.
Burkholderia pseudomallei

Enterobacterales (updated 28 February; temocillin included)
Salmonella spp
Yersinia enterocolitica
Plesiomonas shigelloides
Pseudomonas aeruginosa
Pseudomonas non-aeruginosa
Stenotrophomonas maltophilia (see below for cefiderocol)
Acinetobacter spp. (see below for cefiderocol)
Staphylococcus aureus
Staphylococcus, coagulase-negative
Staphylococcus saprophyticus
Staphylococcus pseudintermedius
Enterococcus spp.
Streptococcus pyogenes (group A)
Streptococcus agalactiae
Streptococcus pneumoniae
Streptococcus pneumoniae - screen for beta-lactam resistance
Viridans Group Streptococci
Haemophilus influenzae
Haemophilus influenzae - screen for betalactam resistance
Moraxella catarrhalis
Anaerobic bacteria (Bacteroides spp, Prevotella spp, Fusobacterium necrophorum, Clostridium perfringens, Cutibacterium acnes)
Listeria monocytogenes
Pasteurella multocida
Campylobacter jejuni and C.coli
Corynebacterium spp.
Aerococcus sanguinicola and urinae
Kingella kingae
Aeromonas spp.
Achromobacter xylosoxidans
Vibrio spp (available 2023)
Bacillus spp.
Burkholderia pseudomallei
Cefiderocol – S. maltophilia and Acinetobacter (neither have clinical breakpoints but can be tested against PK/PD cutoffs)

Enterobacterales
Salmonella spp
Yersinia enterocolitica
Plesiomonas shigelloides
Pseudomonas aeruginosa
Pseudomonas non-aeruginosa
Stenotrophomonas maltophilia (see below for cefiderocol)
Acinetobacter spp. (see below for cefiderocol)
Staphylococcus aureus
Staphylococcus, coagulase-negative
Staphylococcus saprophyticus
Staphylococcus pseudintermedius
Enterococcus spp.
Streptococcus pyogenes (group A)
Streptococcus agalactiae
Streptococcus pneumoniae
Streptococcus pneumoniae - screen for beta-lactam resistance
Viridans Group Streptococci
Haemophilus influenzae
Haemophilus influenzae - screen for betalactam resistance
Moraxella catarrhalis
Listeria monocytogenes
Pasteurella multocida
Campylobacter jejuni and C.coli
Corynebacterium spp.
Aerococcus sanguinicola and urinae
Kingella kingae
Aeromonas spp.
Achromobacter xylosoxidans
Bacillus spp.
Burkholderia pseudomallei
Cefiderocol – S. maltophilia and Acinetobacter (neither have clinical breakpoints but can be tested against PK/PD cutoffs).

Screening for resistance mechanisms using RAST, v 2.0 (12 April 2022 - 18 March, 2025)
Screening for resistance mechanisms using RAST, v 1.0 (valid until 12 April, 2022)
Breakpoints for Rapid AST directly from positive blood culture bottles, v 8.0 (Pdf for printing; 18 March - 14 July, 2025).
Breakpoints for Rapid AST directly from positive blood culture bottles, v 8.0 (Excel-table for screen display;18 March - 14 July, 2025).
Breakpoints for Rapid AST directly from positive blood culture bottles, v 7.2 (Pdf for printing; 23 September, 2024). Error related to Acinetobacter baumannii and ciprofloxacin corrected.
Breakpoints for Rapid AST directly from positive blood culture bottles, v 7.2 (Excel-table for screen display; 23 September, 2024). Error related to Acinetobacter baumannii and ciprofloxacin corrected.
Breakpoints for Rapid AST directly from positive blood culture bottles, v 7.1 (pdf-file for printing; 4 July, 2024)
Breakpoints for Rapid AST directly from positive blood culture bottles , v 7.,1 (Excel-table for screen; 4 July, 2024)
Breakpoints for Rapid AST directly from positive blood culture bottles, v 7.0 (pdf-file for printing; 25 March, 2024)
Breakpoints for Rapid AST directly from positive blood culture bottles, v 7.0 (Excel-table for screen; 25 March, 2024)
Breakpoints for Rapid AST directly from positive blood culture bottles, v 6.1 (pdf-file for printing; 7 June, 2023)
Breakpoints for Rapid AST directly from positive blood culture bottles, v 6.1 (Excel-table for screen; 7 June, 2023)
Breakpoints for Rapid AST directly from positive blood culture bottles, v 6.0 (pdf-file for printing; 25 April, 2023)
Breakpoints for Rapid AST directly from positive blood culture bottles, v 6.0 (Excel-table for screen; 25 April, 2023)
Breakpoints for Rapid AST directly from positive blood culture bottles, v 5.1 (pdf-file for printing; 3 May, 2022) - including a reading time beyond 8 h.
Breakpoints for Rapid AST directly from positive blood culture bottles, v 5.1 (Excel-table for screen; 13 May, 2022) - including a reading time beyond 8 h.
Breakpoints for Rapid AST directly from positive blood culture bottles, v 5.0 (pdf-file, 12 April, 2022; error corrected in version 5.1 above)
Breakpoint tables for Rapid AST directly from blood culture bottles, v 4.0 (pdf-file for printing; 1 January - 12 April, 2022)
Breakpoint tables for Rapid AST directly from blood culture bottles, v 4.0 (Excel-table for screen; 1 January - 12 April, 2022)
Breakpoint tables for Rapid AST directly from blood culture bottles, v 3.0 (pdf-file for printing; 1 January, 2021 - 31 December, 2021)
Breakpoint tables for Rapid AST directly from blood culture bottles, v 3.0 (Excel-table for screen; 1 January, 2021 - 31 December, 2021)
Breakpoint tables for Rapid AST directly from blood culture bottles, v 2.1 (pdf-file for printing; 20 April, 2020 - 30 December, 2020)
Breakpoint tables for Rapid AST directly from blood culture bottles, v 2.1 (Excel-table for screen; 20 April, 2020 - 30 December, 2020)
Breakpoint tables for Rapid AST directly from blood culture bottles, v 2.0 (pdf-file for printing; valid until 20 April, 2020)
Breakpoint tables for Rapid AST directly from blood culture bottles, v 2.0 (Excel-table for screen; valid until 20 April, 2020)
Breakpoint tables for Rapid AST directly from blood culture bottles, v 1.1 (pdf-file for printing); valid until 10 February, 2020.
Breakpoint tables for Rapid AST directly from blood culture bottles, v 1.1 (Excel-table for screen); valid until 10 February, 2020.
Breakpoint tables for Rapid AST directly from blood culture bottles v 1.0 (pdf for printing; valid until 2 May, 2019)
Breakpoint tables for Rapid AST directly from blood culture bottles v 1.0 (Excel for screen; valid until 2 May, 2019)

Previously, EUCAST used the term “intrinsic resistance” to describe isolates which had a resistant expected phenotype. This term was problematic as there is no agreed definition. As clinical breakpoints are always “exposure dependent” it is hard to agree on a definition which will survive changes in dosing, modes of administration and a sudden willingness to accept a new and higher level of toxicity because of a lack of alternatives. The term “expected phenotypes” was adopted in 2022.

Expected resistant phenotypes v 1.1 (25 March, 2022)
EUCAST advice on expected (resistant and susceptible) phenotypes v 1.0 (4 - 25 March, 2022).
EUCAST advice on intrinsic resistance and exceptional phenotypes v 3.3 (4 January, 2022).

Broth microdilution - EUCAST reading guide v 4.0 (1 January 2022)
Broth microdilution - EUCAST reading guide v 3.0 (1 Jan - 31 Dec 2021)
Broth microdilution - EUCAST reading guide v 2.0 (2 Mar - 31 Jan 2020)

Contact

Looking for more information? Get in touch with an EUCAST representative today!

Contact form